{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"The Hidden Cost of Weight Loss Meds: Reevaluating Muscle, Metabolism, and Modern Obesity Treatments","description":"Current and emergent incretin-based therapies (such as GLP-1 and GIP receptor agonists) have transformed obesity treatment by producing unprecedented weight loss. But these benefits come with complexity: significant lean mass loss, raising concerns about metabolic stability, muscle health, and long-term outcomes.&amp;nbsp; &amp;nbsp; In this episode, we briefly revisit the clinical approach to weight-loss medications, connect the foundations of leptin dysregulation with leptin-independent pathways (including the activin\/follistatin\/myostatin\/IGF-1 system), and link these pathways to energy homeostasis and muscle maintenance. We also discuss strategies to preserve lean mass during significant pharmacologically-induced weight reduction. ","author_name":"Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab","author_url":"https:\/\/sites.libsyn.com\/422864","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39144195\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/195753035"}